Beyond Strategic Advancement: Empowering the Future of Diagnostics
We believe technology matters only when it transforms lives. From the very beginning, our mission has been clear: to make
Strategic Technology Transfer
A long-term production and technology transfer agreement with Brazil was signed, reinforcing CHIL’s commitment to sustainable global manufacturing partnerships.
Innovation and Intellectual Property
CHIL initiated patent applications and product development efforts focused on the detection of breast cancer and breast anomalies, signaling a…
Global Representation and Innovation
In April 2023, Dr. Ourania conducted a CORONOMICS interview with Founder Hilda Cil, focusing on the global pandemic and its…
Industry Leadership and Academic Collaboration
On 19 July 2022, CHIL signed a university industry cooperation protocol with Bakırçay University to jointly conduct R&D activities and…
Accelerated Growth
Driven by global demand, CHIL significantly expanded its operational capacity: Manufacturing infrastructure grew to two facilities, including an additional 6,000…
A Defining Year
CHIL became one of the first five companies worldwide to manufacture COVID-19 antigen tests, reinforcing its pioneering position in rapid…
Responding to a Global Crisis
With the onset of the pandemic, CHIL rapidly initiated the in-house production and export of its first antibody tests. This…
Medlab Middle East Dubai
In February 2018, CHIL participated in Medlab Middle East, Dubai. In November 2018, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.
Scaling Capacity
In response to growing operational needs, CHIL transitioned into a 1,000 m² manufacturing facility. This move marked a strategic shift…